Story
Pharming Stock Climbs on Strong Q3 Earnings Beat and Tightened Guidance

Shares in Pharming (AS: PHAR) rose 3.0% to €1.086 after the company reported third-quarter 2026 financial results that significantly surpassed analyst expectations, driven by strong sales growth from its commercial products.
Earnings Exceed Forecasts
Pharming announced a decisive beat on both its top and bottom lines for the third quarter, providing a strong company-specific catalyst for the stock's move while broader markets were largely flat. The Leiden-based firm confirmed the results in its complete financial disclosure.
Key figures from the Q3 2026 report include:
- Revenue: $117.6 million, a 21% year-over-year increase and well above the analyst consensus of approximately $103.5 million.
- Operating Profit: $29.9 million, an 89% jump from the $15.8 million reported in the same period last year.
- Net Profit: $22.4 million, nearly tripling from $7.5 million in Q3 2025, supported by higher revenue and government R&D grants.
Product Performance and Outlook
AdThe revenue growth was fueled by strong performance from both of the company's marketed drugs. Sales of RUCONEST, a treatment for hereditary angioedema, increased 14% to $93.8 million, which the company attributed to demand stabilization and seasonal inventory building. Meanwhile, Joenja (leniolisib) saw revenues surge 58% to $23.8 million, benefiting from strong patient growth in the U.S., new launches in Germany and Japan, and an expanded pediatric label in the U.S.
Looking ahead, Pharming's management tightened its full-year 2026 revenue guidance to a range of $380 million to $390 million, narrowing it from the previous forecast of $375 million to $395 million. This move signals increased confidence in the company's performance for the remainder of the year. Investors are also watching for a near-term pipeline catalyst, with Phase II data for leniolisib in common variable immunodeficiency patients expected in November.
Market Context
The positive earnings report extends a rebound for Pharming's stock, which had been recovering from a difficult period earlier in the year that saw a CEO departure and a guidance cut. The stock's advance was driven by company-specific fundamentals, standing in contrast to a neutral backdrop from major global indices.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.